Replies to post #5368 on Capricor Therapeutics Inc (CAPR)

[GS1]

Takeda deal with Evox is 800M for Evox exosomes platform. That is preclinical asset.

https://www.europeanpharmaceuticalreview.com/news/116115/evox-and-takeda-sign-deal-to-collaborate-on-rare-disease-treatments/